Scientists found that leaking mitochondrial RNA helps pancreatic tumors survive, revealing a promising new treatment target.

In clinical trials, the drug was shown to almost double the median survival time for patients with pancreatic cancer.

Researchers conducted a cross-sectional electronic survey to see whether respondents were offered and completed germline ...

Pancreatic cysts are common and usually considered low risk — but even those lesions signal a significantly elevated and ...

Catching pancreatic cancer early can increase the five-year survival rate from 15% to 80%. Patients with pancreatic cysts, ...

Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve ...

A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients ...

Scientists long ago identified their target: a smooth-surfaced protein inside cells, called KRAS, that is altered in certain ...

The new oral medication, daraxonrasib, has been shown to meaningfully extend the lives of patients with late-stage pancreatic ...

Researchers have uncovered an unexpected weakness in pancreatic cancer involving damaged mitochondria and a powerful ...